Top APAC (Ex-China) Investment Worthy Healthcare Companies Using Smartkarma’s Smart Score Screener
We have screened APAC (ex-China) healthcare companies with market cap≥$800M using Smartkarma’s Smart Score and picked up 2 investable ideas by...
635 Views
Primer: Kissei Pharmaceutical (4547 JP) - Aug 2026
Kissei Pharmaceutical is navigating a period of transition, with strong revenue contributions from key products like Beova and Tavneos being...
97 Views
Kissei Pharma (4547 JP): FY27 Guidance Revealed, Tavneos Hiccup Amid Linzagolix Positives
Kissei Pharmaceutical revenue grows driven by Beova, Tavneos, and IT services despite challenges. Expects drop in revenue for FY27. Linzagolix...
130 Views
Kissei Pharma (4547 JP): 9MFY26 Stable, Guidance Reiterated, Linzagolix Japan Launch Awaited
Kissei Pharmaceutical sees 11% revenue growth in 9MFY26 driven by key products. Expects stable FY26 with focus on Linzagolix (for uterine...
179 Views
Kissei Pharmaceutical (4547 JP): Guidance Upward Revision a Positive; Beova & Tavneos Still Key
Kissei Pharmaceutical received manufacturing and marketing approval from MHLW for its GnRH antagonist Yselty Tablets (Linzagolix) for the...
570 Views